| Evolving management strategies for heparin-induced thrombocytopenia. | Semin Hematol | 2005 Jul | 16105554 |
| Oral anticoagulation: challenges in the case-management setting. | Lippincotts Case Manag | 2005 Jan-Feb | 15685010 |
| Interaction of warfarin with drugs, natural substances, and foods. | J Clin Pharmacol | 2005 Feb | 15647404 |
| Low potential for interactions between melagatran/ximelagatran and other drugs,food, or alcohol. | Semin Vasc Med | 2005 Aug | 16123912 |
| Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. | Clin Pharmacokinet | 2005 | 15871634 |
| Preventing stroke in atrial fibrillation: the SPORTIF programme. | Pathophysiol Haemost Thromb | 2005 | 15812201 |
| Influence of CYP2C9 polymorphisms, demographic factors and concomitant drugtherapy on warfarin metabolism and maintenance dose. | Pharmacogenomics J | 2005 | 15824753 |
| D-003 and warfarin interaction on the bleeding time and venous thrombosisexperimentally induced in rats. | J Med Food | 2004 Summer | 15298777 |
| [New perspectives for anticoagulation in non-rheumatic atrial fibrillation: oral antithrombins]. | Ital Heart J Suppl | 2004 Sep | 15568608 |
| New blood thinner offers first potential alternative in 50 years: ximelagatran. | J Cardiovasc Nurs | 2004 Nov-Dec | 15529058 |